Navigation Links
Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
Date:4/17/2013

ase, acute limb ischemia, and blood transfusions, as well as the timing of activities related to those plans, and prospects for MST-188's clinical, regulatory and commercial success.  Among the factors that could cause or contribute to material differences between the Company's actual results and expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies despite positive results in nonclinical testing and prior clinical studies; the potential for significant delays in the development of MST-188, including due to lack of funding, delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, completing necessary manufacturing process development activities, and being subject to a "clinical hold," or suspension or termination of a clinical study, including due to patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188 in any particular indication in which the Company determines to develop MST-188, including acute limb ischemia, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication or jurisdiction are successful,
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
2. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
8. Halozyme Therapeutics Names Matt Posard to Board of Directors
9. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
10. Cell Therapeutics Secures $15 Million Loan Financing Agreement
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... nebulizer is a medical device used for ... fibrosis) that converts liquid medication into mist or aerosol. ... of a patient when inhaled through the mouth or ... by various devices powered by electric current and rechargeable ... and cystic fibrosis and growing number of geriatric population ...
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... The global market for human vaccines ... of new vaccines. These new products and other ... The Kalorama information report examines the global market ... vaccines for diseases that are already vaccine-preventable. ... communities from diseases spread by person-to-person transmission. The ...
Breaking Medicine Technology:Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
(Date:10/30/2014)... (PRWEB) October 30, 2014 Graphics, coding, ... are synonymous with the craft of web design and ... website. Yet a simpler solution to create a website ... pictures, videos, contact information, customer reviews and Facebook posts ... "It is the next evolution of how a ...
(Date:10/30/2014)... October 30, 2014 Paramount Rx, a ... is increasing efforts to help people save money through ... to increase for prescription drugs in the new health ... and resources to bridge the relationship between consumers, businesses ... the biggest challenges people face today with medical costs ...
(Date:10/30/2014)... Toronto, Canada (PRWEB) October 30, 2014 ... the area’s leading provider of non-medical, in-home senior care, ... activity to increased brain health. , The study, performed ... the ages of 60 and 78 over a week-long ... as opposed to daily physical activity. By examining the ...
(Date:10/30/2014)... REV'D Provision Co. announced today that ... a unique service called, The Feed . The ... everyday athlete. The Feed has taken the nutritional knowledge ... system to pass that information on to the everyday ... available on The Feed!” says REV’D® marketing manager Matt ...
(Date:10/30/2014)... it comes to heart disease, a new study finds women ... have symptoms that spell trouble. "The main danger is ... severe or advanced stage of heart disease, there are simply ... Scholar and research fellow at the Harvard School of Public ... Stroke Foundation of Canada. In the study, researchers talked ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2
... operation, a team of doctors here sucessfully removed a 'minute ... 11-month-old (RPT 11-month-old) boy. // ,Dr Palaniappan of ... perform the operation recently, told PTI here that Muniraj was ... food for the last one-and-a-half months., ,After trying different ...
... it would raise 16 million dollar through the issue Foreign ... company would allot 16,000 FCCBs of 1,000 dollar each to ... Singapore Stock Exchange, Ankur Drugs informed the Bombay Stock Exchange., ... 14,000 FCCBs while 1,000 FCCBs would be given to DKR ...
... transmission of the deadly bird flu virus among members of ... has sought to assure the public that potentially dangerous mutation ... maintained that human contagion cannot be ruled out in the ... far there has been no evidence that efficient human-to-human transmission ...
... outbreak of bird flu at a poultry farm in Kakara ... ,Timothy Obi, leader of the Avian Influenza task force ... reporters that the institute claimed to have diagnosed samples of ... infected with the deadly H5N1 virus. ,An official ...
... has been announced states that all the state schools are to ... This is part of their drive against obesity. , ... milk to pupils aged 3 to 18. The ruling also applies ... and to cartons sold in vending machines. ,This ban ...
... that is available in the British Medical Journal has suggested that ... the heart // , but these benefits seem to favor men ... on 50,000 Danish men and women in the age bracket of ... study did show that women who took alcohol at least one ...
Cached Medicine News:Health News:Fresh Outbreak Of Bird Flu In Nigeria 2Health News:All State Run Schools Are To Ban Whole Milk To Children 2Health News:All State Run Schools Are To Ban Whole Milk To Children 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: